Fondren Management’s Harvard Bioscience HBIO Stock Holding History

Fondren Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,000	Closed	-$221K	–	40
2020 Q1	$221K	Sell	10,000 -29,300	-75%	-$794K	0.56%	45
2019 Q4	$1.2M	Sell	39,300 -47,200	-55%	-$1.36M	1.23%	25
2019 Q3	$2.66M	Buy	86,500 +40,607	+88%	+$1.01M	2.21%	13
2019 Q2	$918K	Buy	45,893 +30,893	+206%	+$905K	0.87%	34
2019 Q1	$647K	Buy	+15,000	New	+$544K	0.52%	43
2017 Q1	–	Sell	-23,000	Closed	-$702K	–	44
2016 Q4	$702K	Buy	+23,000	New	+$585K	0.5%	41

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Fondren Management's HBIO Position: Q2 2020 in Review

Fondren Management sold out of Harvard Bioscience (HBIO) in Q2 2020, closing a stake of 10,000 shares — an estimated $221K sold.

Fondren Management first reported a position in HBIO in Q4 2016 and held it in 6 quarters. The position peaked at $2.66M in Q3 2019. 87 funds tracked by Wall St. Rank hold HBIO as of Q2 2020.

Fondren Management reported no remaining Harvard Bioscience position as of Q2 2020 after selling out during the quarter.
Fondren Management sold 10,000 Harvard Bioscience shares in Q2 2020, an estimated $221K.
Fondren Management first reported a position in Harvard Bioscience in Q4 2016 and held it in 6 quarters.
Fondren Management's Harvard Bioscience position peaked at $2.66M in Q3 2019.
87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2020.

Based on Fondren Management's 13F filing for Q2 2020, filed 14 Aug 2020.